Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Please write to us at: Contact@qvents.in
We value your feedback on the Posts, Discussions, Information presented by Qvents. Also write to us on other pharma Quality and Regulatory subjects which you would like Qvents to address. Your feedback helps us making and maintaining the Qvents portal as a useful resource for Pharma professionals
You can also write to us on different Quality events (Deviations, OOS, Complaints, CAPAs and so on), Warning letters, 483s, Recalls, Import Alerts, Audit observations) you would like Qvents to initiate posts and discussions. We will review and get back to you, take up the subjects for discussion in Qvents.
Please also write to us for general feedback, quality of contents, any irrelevant or offensive posts, threads, comments
USP has launched a WhatsApp channel. Through the channel, followers will receive updates in USP standards and solutions, sicntific insights on biologics, APIs, excipients, impurities; Industry news and resources, webinars, workshops US Pharmacopeia_India | WhatsApp Channel
In September 2025, the USFDA classified Sun Pharmaceutical Industries Ltd.’s Halol facility as OAI (Official Action Indicated) following a inspection conducted from June 2–13, 2025. The inspection conducted by USFDA investigators—Justin A Boyd, Pratik S. Upadhyay, and Lisa L. Flores—identified...
Government of India is amending the New Drugs and Clinical Trials (NDCT) Rules 2019 permitting manufacture a new drug or an investigational new drug for clinical trials, BA/BE studies or examination, test and analysis after submitting online application for notification...
We value your feedback on the Posts, Discussions, Information presented by Qvents. Also write to us on Pharma Quality and Regulatory topics and subjects you would like Qvents to cover. Your feedback helps us in making and maintaining the Qvents portal as a useful resource for Pharma TechOps professionals. Please also write to us for general feedback, quality of contents, any irrelevant or offensive posts, threads, comments
Please feel free to contact us for any enquiries.
Email: contact@qvents.in
Phone: (+91) 9945519525
We value your feedback on the Posts, Discussions, Information presented by Qvents. Also write to us on Pharma Quality and Regulatory topics and subjects you would like Qvents to cover. Your feedback helps us in making and maintaining the Qvents portal as a useful resource for Pharma TechOps professionals. Please also write to us for general feedback, quality of contents, any irrelevant or offensive posts, threads, comments
Please feel free to contact us for any enquiries.
Email: contact@qvents.in
Phone: (+91) 9945519525
USP has launched a WhatsApp channel. Through the channel, followers will receive updates in USP standards and solutions, sicntific insights on biologics, APIs, excipients, impurities; Industry news and resources, webinars, workshops US Pharmacopeia_India | WhatsApp Channel
In September 2025, the USFDA classified Sun Pharmaceutical Industries Ltd.’s Halol facility as OAI (Official Action Indicated) following a inspection conducted from June 2–13, 2025. The inspection conducted by USFDA investigators—Justin A Boyd, Pratik S. Upadhyay, and Lisa L. Flores—identified...
Government of India is amending the New Drugs and Clinical Trials (NDCT) Rules 2019 permitting manufacture a new drug or an investigational new drug for clinical trials, BA/BE studies or examination, test and analysis after submitting online application for notification...
